Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Equities

Biosergen AB

Biosergen AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)0.634
  • Today's Change0.004 / 0.63%
  • Shares traded167.97k
  • 1 Year change-27.05%
  • Beta--
Data delayed at least 15 minutes, as of Sep 24 2024 14:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biosergen AB is a Sweden-based biotechnology company. It carries out biopharmaceutical research and development through its Subsidiary Biosergen AS from laboratory facilities in Trondheim, Norway and several other places worldwide. The Company is developing BSG005, a potentially disruptive antifungal drug which has demonstrated safety and potency advantages over competing antifungals. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS, cancer and transplant patients every year. At equal dose levels BSG005 has demonstrated a three-to-fouold potency advantage against the relevant fungal strains compared to the current standard of care, while being completely free of the kidney toxicity hampering other drugs in its class.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-26.60m
  • Incorporated2021
  • Employees2.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Prolight Diagnostics AB (publ)0.00-140.00m102.14m16.00--0.6989-----0.3853-0.38530.000.24470.00----0.00-66.82---89.89--------------0.00-----------13.84--
Active Biotech AB publ0.00-44.20m108.52m8.00--11.31-----0.1564-0.15640.000.02650.00-------189.29-57.97-322.63-97.83-------1,454.61----0.1933------21.54------
AroCell AB (publ)48.29m-53.73m120.94m----0.8635--2.50-0.2333-0.23330.20960.608-----------29.25---31.378.63-9.85-111.28-231.194.61--0.00--16.37122.92-0.5494------
NextCell Pharma AB11.85m-37.28m128.64m----1.63--10.85-0.8565-0.85650.27231.080.151244.637.34---47.56-34.92-54.11-37.06-193.25-349.19-314.54-538.603.75--0.00--80.9672.85-15.21------
Exact Therapeutics AS0.00-46.95m155.82m8.00--3.56-----1.51-1.510.001.410.00-------67.21-40.21-86.14-45.67-----------16,578.570.0258-------20.52------
Biosergen AB0.00-26.60m174.86m2.00--11.31-----0.286-0.2860.000.05570.00----0.00-145.58---216.30--------------0.00------32.25------
Lumito AB (publ)17.00k-26.38m182.05m14.00--1.69--10,708.57-0.1268-0.12680.000080.45980.0001--0.00961,133.33-20.54-20.77-23.68-22.3844,594.29---155,169.10--1.32-24.400.1569------4.56------
AlzeCure Pharma AB0.00-35.87m182.77m11.00--4.48-----0.5371-0.53710.000.46250.00----0.00-75.21-52.78-89.05-57.01------------0.00------33.91------
Acousort AB3.44m-19.30m203.10m----13.28--59.06-1.33-1.330.23791.020.14614.081.96---81.99-48.62-137.70-69.77-159.41-68.05-561.21-299.581.91--0.00--11.5138.81-24.01------
SenzaGen AB55.29m-20.60m206.53m32.00--2.25--3.74-0.8299-0.82992.233.110.50193.325.801,626,029.00-18.70-25.84-23.34-29.8571.6368.62-37.27-132.292.76-51.340.0443--19.3990.3211.30---21.10--
Biovica International AB7.25m-115.45m222.38m27.00--2.49--30.67-1.73-1.730.10551.060.058417.304.76226,593.80-92.98-51.94-110.37-58.18-394.72-576.01-1,592.15-2,217.413.47--0.0721--115.4919.39-12.97---54.31--
Ascelia Pharma AB0.00-61.78m231.07m13.00--2.52-----1.26-1.260.000.95540.00----0.00-52.75---65.92-------------40.420.4167------16.72------
Thor Medical ASA0.00-18.03m233.62m1.00--0.925-----0.08730.0210.001.110.00----0.00-9.82-79.17-10.54-113.94------------0.0035--------------
Kancera AB0.00-53.07m236.31m5.00--2.85-----0.5955-0.59550.000.68490.00----0.00-56.73-54.82-66.40-66.21--96.28---7,249.06----0.00-------23.64------
Xbrane Biopharma AB191.89m-340.89m240.13m71.00--0.7885--1.25-1.01-1.260.34030.19910.2090.702824.132,063,301.00-37.14-40.98-66.96-67.2443.32---177.65-364.401.07-20.510.357--314.3363.42-91.10--60.02--
Data as of Sep 24 2024. Currency figures normalised to Biosergen AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.